Ataxia-Telangiectasia: An Emerging Role For Inflammation In Driving Neurodegeneration And Premature Ageing
Funder
National Health and Medical Research Council
Funding Amount
$437,436.00
Summary
Ataxia-Telangiectasia (A-T) is a devastating genetic disease that arises in early childhood and causes patients to die in their twenties. To date there is no cure, and therapeutics are desperately needed. This project will use state-of-the-art brain organoids derived from stem cells of A-T patients in order to better understand this disease and evaluate novel drugs that target the molecular mechanisms that drive chronic inflammation and brain neurodegeneration in children with A-T.
Understanding The Molecular Mechanisms Of Cell Death In Radiotherapy
Funder
National Health and Medical Research Council
Funding Amount
$643,856.00
Summary
Radiotherapy (RT) is responsible for 40% of cancer cures. New technology enables RT delivery in fewer treatments using higher radiation dosages through a technique called 'ART'. While ART is effective in the clinic, the underlying mechanisms of cancer cell death are unclear. Here we show that ART induces two distinct waves of cancer cell death. We will characterize these waves of cell death and determine how to enhance tumour cell killing with pharmacological intervention.
Identification Of Novel Mediators Of Bone Catch-up Growth
Funder
National Health and Medical Research Council
Funding Amount
$1,043,810.00
Summary
Musculoskeletal growth disorders cause significant suffering in children and impair new workforce generations before their working life starts. Despite this relevance, non-invasive methods to induce growth recovery of impaired bones are an unmet need, as we lack sufficient understanding of how this process works. To address this knowledge gap, we generated mouse models that will allow us to reveal foetal mediators of compensatory growth that could be reactivated postnatally to boost bone growth.
We aim to discover and develop a blood test that can predict which lung cancers have spread to lymph glands in the chest, to help decide on the best treatment options.
Modulating COVID-19 Disease By Targeting Virus And Virus-induced Responses Through Pharmaceutical And Mechanical Ventilation Strategies: SARS-CoV-2 S-protein, ACE2 And TMPRSS2
Funder
National Health and Medical Research Council
Funding Amount
$628,856.00
Summary
COVID-19 is a current global pandemic that is likely to be an on-going threat. We need a multipronged strategy to combat COVID-19, including therapeutic anti-virals and clinical practice management strategy. We will address both these points to define the mechanisms triggering disease, test existing drugs targeting androgens and modify the way doctors use ventilators to treat COVID-19 disease in the intensive care unit. Outcomes will have impact beyond COVID-19 for managing viral lung disease.